Peripheral neuropathy in hematologic malignancies - Past, present and future.
Blood Rev
; 43: 100653, 2020 09.
Article
in En
| MEDLINE
| ID: mdl-31983507
ABSTRACT
Neurotoxic treatments (including proteasome inhibitors, immunomodulatory drugs and vinca-alkaloids) are often used in the treatment of hematologic malignancy. Peripheral neuropathy can be part of a paraneoplastic syndrome accompanying the disease but more commonly is a consequence of treatment with neurotoxic therapies, and produces sensory, motor, autonomic nerve dysfunction or a combination, leading to pain, loss of sensation and functional disability. This review provides an update on peripheral neuropathy in hematologic malignancy, including risk factors, mechanisms and treatment options. We examine the clinical features and risk factors for peripheral neuropathy following bortezomib, thalidomide, brentuximab vedotin and vinca alkaloid treatment, as well as related compounds. We review the current data on pharmacogenetic risk factors for the development of toxicity and highlight areas of future research.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vinca Alkaloids
/
Peripheral Nervous System Diseases
/
Hematologic Neoplasms
/
Proteasome Inhibitors
/
Immunologic Factors
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Blood Rev
Journal subject:
HEMATOLOGIA
Year:
2020
Document type:
Article
Affiliation country:
Australia